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Summary
Anti-neutrophil cytoplasmic antibodies (ANCA) appear to play an
important role in the pathogenesis of ANCA-associated vasculitis (AAV).
However, ANCA alone are not sufficient to generate disease, and some
evidence suggests that infectious triggers may serve as inciting events for
AAV disease activity. Antibodies of the immunoglobulin (Ig)M isotype often
serve as markers of recent infection, and IgM ANCA have been identified
previously in patients with AAV, although the frequency and clinical
relevance of IgM ANCA is not well established. We sought to characterize
IgM ANCA more clearly by creating a novel enzyme-linked immunosorbent
assay (ELISA) for IgM antibodies to proteinase 3 [IgM proteinase 3 (PR3)–
ANCA], which we applied to two large, clinically well-characterized trial
cohorts of patients with granulomatosis with polyangiitis and microscopic
polyangiitis. In the first cohort, IgM PR3–ANCA occurred with a frequency
of 150%, and were associated with a higher degree of disease severity and a
trend towards a higher rate of alveolar haemorrhage (296 versus 157%,
P5 010). Analysis of follow-up samples in this cohort showed that the
presence of IgM PR3–ANCA was transient, but could recur. In the second
cohort, IgM PR3–ANCA occurred with a frequency of 411%, and were also
associated with a higher degree of disease severity. A higher rate of alveolar
haemorrhage was observed among those with IgM PR3–ANCA (453 versus
158%; P< 0001). The association of transient IgM PR3–ANCA with an
acute respiratory manifestation of AAV suggests a possible link between an
infectious trigger and AAV disease activity.
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Introduction
The anti-neutrophil cytoplasmic antibody (ANCA)-associ-
ated vasculitides (AAV) are defined in most patients by
characteristic clinical and histopathological features and
the presence of ANCA [1]. However, patients with AAV
present heterogeneously, to the extent that three separate
clinicopathological variants of AAV have been defined:
granulomatosis with polyangiitis (GPA, formerly Wegener’s
granulomatosis), microscopic polyangiitis (MPA) and
eosinophilic granulomatosis with polyangiitis (EGPA, for-
merly Churg–Strauss syndrome). Even within these syn-
dromes the inflammatory activity can affect different organ
systems in different patients, and in any single patient the
organs affected and the severity of disease activity can vary
over time [2].
Our understanding of the pathogenesis of AAV has
improved significantly over the last couple of decades,
allowing a more targeted approach to therapy. However,
many important questions remain unanswered. In predis-
posed patients abnormal T and B lymphocyte regulation
leads to the production of ANCA, and their role in neutro-
phil and monocyte activation seem to be crucial for the
development of disease manifestations such as glomerulo-
nephritis or pulmonary capillaritis, although ANCA alone
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are not sufficient for the disease process to play out fully in
humans [3–5]. Moreover, the specific triggers of a primary
ANCA immune response, such as infections, and the mech-
anisms leading subsequently to the loss of tolerance and
persistence of ANCA in predisposed patients remain
unclear.
The most prevalent and best-studied ANCA with
accepted diagnostic utility are of the immunoglobulin
(Ig)G isotype. IgM ANCA and IgA ANCA have also been
identified [6–9]. Early studies investigating the clinical sig-
nificance of the various ANCA isotypes suggested an asso-
ciation of circulating IgM ANCA with certain disease
manifestations, particularly alveolar haemorrhage [6,10].
However, these associations and their clinical relevance
were questioned by others [7,11,12]. Because these early
reports on IgM ANCA were derived from somewhat small
cohorts, and the theory of infections as triggering co-
factors of disease development and activity has persisted
for decades, we conducted the present study to revisit the
prevalence and clinical associations of IgM PR3–ANCA in
two large clinically well-characterized trial cohorts.
Material and methods
Patient populations
The study population consisted of two cohorts. The partic-
ipants of the Wegener’s Granulomatosis Etanercept Trial
(WGET) comprised the first cohort, and the subset of 129
PR3–ANCA-positive subjects enrolled into in the Rituxi-
mab versus Cyclophosphamide for AAV trial (RAVE) made
up the second cohort. We chose to study the two cohorts
separately for two principle reasons: first, the entrance cri-
teria of the two studies differed significantly, so there is
substantial heterogeneity between the two groups; and sec-
ondly, the separation of the two cohorts provided the
opportunity to test and validate associations identified in
our study of the first cohort. All patients enrolled into the
trials provided written informed consent that included
consent for the use of biospecimens in ancillary studies,
and both trials were approved by the institutional review
boards at each participating site.
The design of WGET, the baseline clinical characteristics
of study participants and the primary trial results have
been described in detail elsewhere [13,14]. Briefly, WGET
was a multi-centre, randomized, placebo-controlled trial
that evaluated the use of etanercept for remission mainte-
nance in GPA. The WGET study population consisted of
180 patients who were enrolled at eight centres across the
United States. Each patient who enrolled in WGETmet the
following criteria: (1) the diagnosis of GPA was supported
by fulfilling at least two of the five modified American Col-
lege of Rheumatology criteria for the classification of
Wegener granulomatosis, and (2) there was evidence of dis-
ease activity within 28 days of enrolment, with a
Birmingham Vasculitis Activity Score for Wegener Granu-
lomatosis (BVAS/WG) of at least 3 [15].
The details of the design of RAVE, along with the partici-
pants’ baseline clinical data and the trial’s primary results,
have been reported elsewhere [16,17]. Briefly, RAVE was a
multi-centre, randomized, double placebo-controlled trial
that compared the efficacy and safety of rituximab with
cyclophosphamide for remission induction in severe AAV.
The RAVE study population consisted of 197 patients
enrolled at eight centres in the United States and one centre
in the Netherlands. All patients met 1994 Chapel Hill Con-
sensus Conference definitions for the diagnosis of GPA or
MPA, had positive serum assays for PR3–ANCA or myelo-
peroxidase (MPO)–ANCA at the time of enrolment, had
active disease with a minimum BVAS/WG of 3 and had
received glucocorticoids for no longer than 14 days prior to
study screening. In addition, all patients were classified as
having ‘severe’ AAV, defined as disease activity involving a
vital organ and posing an immediate threat to that organ’s
function or to the patient’s life.
Patient evaluations and sample collections
Patients in WGET were evaluated during study visits that
occurred at baseline, after 6 and 12 weeks, and then every
3 months until the trial ended [14]. RAVE participants
were evaluated during study visits at baseline, and then on
a regular schedule for at least 18 months [17]. At every
study visit disease activity was measured using the BVAS/
WG instrument, and serum samples were drawn in both
WGET and RAVE. Serum samples were frozen and stored
at280 C.
ANCA assays
IgG ANCA assays had been performed previously in both
study cohorts using standard immunofluorescence and
enzyme immunoassays [4,5,17,18]. A novel capture
enzyme-linked immunosorbent assay (ELISA) was
designed to detect PR3–ANCA of the IgM isotype in
patient serum. The capture ELISA used poly-His tagged
recombinant PR3 (rPR3) [19] bound to nickel-coated
plates to test for anti-rPR3 reactivity in serum samples
diluted 1 : 20 in Tris-buffered saline (TBS) containing 05%
bovine serum albumin (BSA). The presence of IgM anti-
bodies bound to rPR3 were detected using a goat
anti-human IgM (l-chain specific)-alkaline phosphatase
antibody (Sigma-Aldrich, St Louis, MO, USA), diluted
1 : 20 000 in TBS buffer containing 05% BSA. The assay’s
cut-off value for a positive result was determined by per-
forming the test on 37 samples drawn from patients who
had tested negative previously for PR3–ANCA by standard
clinical assays for IgG PR3–ANCA. All 37 of these samples
were derived from waste material from the clinical immu-
nology laboratory at Mayo Clinic, Rochester, Minnesota. In
each instance, PR3–ANCA testing had been ordered by a
IgM PR3–ANCA in GPA and MPA
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treating clinician, and the result had been negative. The
cut-off value for a positive result for the novel IgM PR3–
ANCA capture ELISA was set at 4 standard deviations
(s.d.) above the mean of the assay’s results from these 37
samples. This conservative cut-off value was chosen to
minimize the problem of borderline positivity.
To assess the epitope specificity of IgM PR3–ANCA we
used monoclonal antibodies with defined PR3 epitope
specificity as capturing antibodies in capture ELISAs, as
described previously for IgG ANCA detection [20–22].
Immulon strips were coated with the monoclonal antibod-
ies mouse monoclonal proteinase 3 (PR3) antibody
(MCPR3)22, MCPR3-3 or MCPR3-7 prior to loading the
rPR3 antigen. Bound IgM PR3–ANCA was detected as
described above.
Statistical analysis
Continuous variables are presented as median [interquar-
tile ranges (IQR)] and categorical variables are presented as
counts and percentages, unless specified otherwise. Associ-
ations between binary measures were performed with the
use of Fisher’s exact test, as appropriate, while associations
between continuous variables were performed with Wilcox-
on’s rank-sum test. Statistical analyses were performed
using JMP version 10.0.
Results
IgM PR3–ANCA in the WGET cohort
Serum samples from the baseline visit were available for all
180 patients enrolled in WGET. The key clinical character-
istics of this cohort are summarized in Table 1. A full
description of the cohort’s baseline clinical and disease
characteristics has been published elsewhere [14]. The
cohort included patients with both severe (711%) and lim-
ited or non-severe (289%) GPA, and patients in whom
enzyme immunoassay testing for IgG PR3–ANCA had
been either positive (728%) or negative (272%).
Twenty-seven of the 180 WGET baseline samples
(150%) tested positive for IgM PR3–ANCA. IgM PR3–
ANCA were detected among subjects with both limited and
severe disease as well as with both newly and previously
diagnosed GPA, but only among those who had been found
to have IgG PR3–ANCA by standard clinical assays (Table
2).
The disease activity at baseline was higher among
patients who tested positive for IgM PR3–ANCA [median
(IQR) BVAS/WG of 7.5 (5–12)] compared to those who
tested negative [BVAS/WG of 6 (4–85); P5 0.02] (Fig. 1).
The organ systems involved by GPA did not differ
according to IgM PR3–ANCA status, but there was a nota-
ble trend towards more frequent alveolar haemorrhage
among those who tested positive for IgM PR3–ANCA.
Alveolar haemorrhage was diagnosed at baseline in eight of
the 27 patients (296%) who tested positive for IgM PR3–
ANCA, compared to 24 of the 153 patients (157%) who
tested negative (P5 010). This trend was also seen when
the analysis was restricted to the 128 WGET patients with
severe GPA, who are more likely to have detectable ANCA
[18]. Among the 128 patients with severe GPA, alveolar
haemorrhage was diagnosed in eight of the 19 patients
(421%) with a positive IgM PR3–ANCA test result and 24
of the 109 patients (220%) who tested negative (P5 008).
Among the 32 WGET patients who had been diagnosed
with alveolar haemorrhage at the baseline visit, further IgM
PR3–ANCA assays were performed on serum samples from
all available subsequent study visits, as summarized in
Fig. 2. Twenty-four of these 32 patients had tested negative
for IgM PR3–ANCA at the baseline visit, and the test
remained negative for all 24 patients at all follow-up visits.
The remaining eight patients had tested positive for IgM
Table 1. Patient characteristics
Clinical characteristics WGET cohort* RAVE cohort**
(n 5 180) (n 5 129) P-value
Age (mean6 s.d.) 49.96 15.3 49.86 14.8 0.95
Gender (% male) 60.0% 58.1% 0.74
Race
White, non-Hispanic 92.2% 93.0% 0.79
Black, non-Hispanic 1.7% 2.3%
Other 6.1% 4.6%
Disease onset
New-onset 44.1% 37.2% 0.20
Recurrent 55.9% 62.8%
BVAS-WG (mean6 s.d.) 7.06 3.4 8.06 3.2 0.01
Alveolar haemorrhage 17.8% 27.9% 0.04
Major renal involvement 35.0% 44.2% 0.12
*Derived from the Wegener’s Granulomatosis Etanercept Trial
(WGET) [14].
**Derived from the Rituximab versus Cyclophosphamide for AAV
trial (RAVE) [17].
Table 2. Disease characteristics by immunoglobulin (Ig)M proteinase
3–anti-neutrophil cytoplasmic antibodies (PR3–ANCA) status, Wege-





(n 5 27) (n 5 153) P-value
IgG PR3–ANCA, n (%)
 Positive 27 (100) 121 (79) 0.005
 Negative 0 (0) 32 (21)
Timing of diagnosis, n (%)
 New diagnosis 16 (59) 64 (42) 0.10
 Previous diagnosis 11 (41) 89 (58)
Disease severity, n (%)
 Severe 19 (70) 109 (71) 1.0
 Limited 8 (30) 44 (29)
J. M. Clain et al.
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PR3–ANCA at the baseline visit. At follow-up, only one of
the eight patients had a persistently positive IgM PR3–
ANCA test at the week 6 visit, and that patient’s test con-
verted to negative at the week 12 visit. Subsequently, IgM
PR3–ANCA re-emerged in four of the eight patients.
Among the four WGET patients who were diagnosed
with alveolar haemorrhage at baseline and who tested posi-
tive for IgM PR3–ANCA at multiple time-points during
the study, the target epitopes of the identified IgM PR3–
ANCA were studied further. In one of the four patients, the
IgM PR3–ANCA epitope target appeared to remain con-
stant over time, but epitope variability was apparent in
serial samples from the remaining three patients. The lon-
gitudinal results from two of the four patients are repre-
sented in Fig. 3, which displays the capture ELISA results
for both IgG and IgM PR3–ANCA at each sequential study
encounter, and shows the epitope binding pattern of the
IgM PR3–ANCA for each instance at which it is detected.
Two key points are highlighted in Fig. 3. First, the longitu-
dinal ELISA results show that the waxing and waning of
IgM and IgG PR3–ANCA levels appear independent. That
is, the emergence and disappearance of IgM PR3–ANCA in
an individual do not simply follow the rise and fall of the
overall ANCA level. The second point highlighted in Fig. 3
is that the epitope binding pattern of the IgM PR3–ANCA
can change (as seen in patient 1) or remain stable (as seen
in patient 2) over time.
IgM PR3–ANCA in the RAVE cohort
The RAVE cohort was used to investigate further the most
interesting observation made in the WGET cohort: the
potential association between the presence of IgM PR3–
ANCA and the diagnosis of alveolar haemorrhage. Serum
samples from all 129 RAVE patients who had tested posi-
tive for IgG PR3–ANCA by standard clinical assays were
included in the cohort. The key clinical characteristics of
the cohort are summarized in Table 1. As a condition of
inclusion in the RAVE trial, all patients had severe GPA or
MPA. Thirty-six of the 129 PR3–ANCA-positive patients
Fig. 1. Disease severity, as measured by BVAS/WG score, at baseline
visit in WGET cohort, by immunoglobulin (Ig)M proteinase 3–anti-
neutrophil cytoplasmic antibodies (PR3–ANCA) status.
Fig. 2. Change in immunoglobulin (Ig)M
proteinase 3–anti-neutrophil cytoplasmic
antibodies (PR3–ANCA) over time in
patients with alveolar haemorrhage in the
Wegener’s Granulomatosis Etanercept Trial
(WGET) cohort.
IgM PR3–ANCA in GPA and MPA
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(279%) were diagnosed with alveolar haemorrhage at the
baseline visit.
The IgM PR3–ANCA assay was performed on serum
samples obtained at the baseline visit. IgM PR3–ANCA
were detected in 53 of the 129 patients (411%). As had
been observed in the WGET cohort, those who tested
positive for IgM PR3–ANCA had higher levels of disease
activity compared to those who tested negative (Fig. 4).
Fig. 3. Longitudinal results of immunoglobulin (Ig)M proteinase 3–anti-neutrophil cytoplasmic antibodies (PR3–ANCA) enzyme-linked
immunosorbent assay (ELISA), IgM PR3–ANCA ELISA and IgM PR3–ANCA epitope binding pattern assays for two patients who were
diagnosed with alveolar haemorrhage at baseline and who tested positive for IgM PR3–ANCA at multiple time-points during the Wegener’s
Granulomatosis Etanercept Trial (WGET) study. (a, b) The results of ELISA assays for IgG PR3–ANCA (a) and IgM PR3–ANCA (b) performed
on sera drawn from patient 1 across longitudinal study visits; (d, e) similarly display longitudinal results of the same assays from sera drawn
from patient 2. For both patients, fluctuations in the IgG PR3–ANCA levels and the IgM PR3–ANCA levels occur independently. (c) Results of
the IgM PR3–ANCA epitope binding assays performed on sera drawn from patient 1, restricted to time-points at which the antibody was
detected. (f) Results of the same assays performed on sera drawn from patient 2. Mouse monoclonal proteinase 3 (PR3) antibody (MCPR3)22,
MCPR3-3, and MCPR3-7 refer to the monoclonal antibodies used as capturing antibodies for the epitope binding assays. Changes in the pattern
of results among these assays are suggestive of changes in the epitope binding site of the patient’s IgM PR3–ANCA over time. (c, f) Highlight
that the IgM PR3–ANCA epitope binding site appears to change over time for patient 1 (c), but not for patient 2 (f).
J. M. Clain et al.
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The median (IQR) baseline BVAS/WG was 9 (6–10) among
those who tested positive for IgM PR3–ANCA and 7 (5–
975) among those who tested negative (P 5 005). As with
the WGET cohort, the frequencies of newly diagnosed and
recurrent AAV were similar among patients with and with-
out IgM PR3–ANCA. The rate of newly diagnosed AAV
was 358% among patients who tested positive for IgM
PR3–ANCA and 382% among patients who tested nega-
tive (P5 085).
Alveolar haemorrhage was diagnosed nearly three times
more frequently among those who tested positive for IgM
PR3–ANCA compared to those who tested negative (453
versus 158%; P < 0001). In contrast, the frequency of
major renal disease at baseline was similar among patients
who tested positive for IgM PR3–ANCA compared to those
who tested negative (472 versus 421%; P5 059).
Discussion
With the use of a novel assay for IgM PR3–ANCA, we have
shown that ANCA of the IgM isotype are present in certain
patients with active AAV, and that the presence of IgM
PR3–ANCA is associated with increased disease activity
and with alveolar haemorrhage. To our knowledge, these
are the largest cohorts on which IgM ANCA testing has
been reported. Both the finding of IgM ANCA and the
apparent association with the most acute respiratory mani-
festation of disease are of interest with respect to disease
pathogenesis, as they suggest a possible link to infection.
Infections have often been implicated in the develop-
ment of autoimmune diseases. However, their specific roles
remain poorly defined. Many theories have connected
autoimmune diseases to antecedent infections, with poten-
tial mechanisms including molecular mimicry, epitope
spreading and the release of hidden antigens, among others
[23]. In certain autoimmune diseases, the connection has
been made convincingly. For example, in Guillain–Barre
Syndrome, in which acute gastroenteritis caused by Campy-
lobacter jejuni frequently precedes the development of the
syndrome’s neurological manifestations, structural similar-
ities and antibody cross-reactivity have been identified with
respect to C. jejuni’s lipopolysaccharide and components of
peripheral nerves [24–26].
In AAV, infections have not been tied definitively to dis-
ease pathogenesis, but several observations have suggested
that infectious agents may play an important role in the
development of AAV and in its course. For instance, several
but not all epidemiological studies have reported seasonal
variations in the frequency of presentation of AAV, as
would be expected in an infection-mediated disease
[27–32]. In addition, the development of circulating
ANCA during infections has been described worldwide,
most notably in association with infectious endocarditis,
although the clinical relevance of these antibodies remains
unclear [33–35]. In terms of specific organisms, special
consideration has been given to Staphylococcus aureus.
Chronic nasal colonization with S. aureus has been
reported to occur more frequently in patients with GPA
than in healthy controls and, among those with GPA, nasal
colonization with S. aureus has been associated with a
higher risk of disease relapse [3,36].
As with these observations, our finding of transient IgM
PR3–ANCA in substantial numbers of patients can be seen
as suggestive of a link between AAVand an infectious expo-
sure. A short-lived rise in antigen-specific IgM antibodies
is the expected initial humoral response to pathogen expo-
sure. In theory, this initial IgM phase of the humoral
response is particularly susceptible to self-cross-reactivity,
as the majority of IgM antibodies are polyreactive, due to
low affinity and high valency properties [37,38]. It is there-
fore possible that the IgM PR3–ANCA has been triggered
by an infectious stimulus, analogous to the development of
cold haemagglutinins following exposure to Mycoplasma
pneumoniae [39,40]. Along these lines, the finding of an
association between the presence of IgM PR3–ANCA and
alveolar haemorrhage supports the possibility of an infec-
tious trigger, as we would speculate that alveolar haemor-
rhage is more likely in the setting of respiratory
inflammation secondary to an infectious insult. Future
studies will be required to investigate the association
between IgM PR3–ANCA and respiratory infections.
Beyond speculation, there are significant differences
between the two trial cohorts to consider as they may
explain differences in results. The enrolment criteria of the
Fig. 4. Disease severity, as measured by Birmingham Vasculitis
Activity Score for Wegener Granulomatosis (BVAS/WG) score, at
baseline visit in the Rituximab versus Cyclophosphamide for AAV
trial (RAVE) cohort, by immunoglobulin (Ig)M proteinase 3–anti-
neutrophil cytoplasmic antibodies (PR3–ANCA) status.
IgM PR3–ANCA in GPA and MPA
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two trial protocols differed enough for patients in the
WGET cohort being less acutely ill, on average, than those
in the RAVE cohort. This difference in acuity derives in
part from differences in disease manifestations, as patients
with non-severe disease were included in WGET but not in
RAVE. It also derives from the fact that the time from the
symptom onset of the disease episode leading to enrolment
tended to be longer in WGET than in RAVE. As the IgM
response is expected to be short-lived, it is possible that the
difference in frequency of IgM PR3–ANCA observed in the
two cohorts is due in part to the timing of study enrol-
ment; that is, the IgM response in some WGET patients
could have been ‘missed’.
The potential to miss the coming-and-going of IgM
ANCA is an important point that has been highlighted pre-
viously in the literature. Certain original descriptions of
IgM ANCA suggested a strong correlation with alveolar
haemorrhage [6,10]. However, other investigators cast
doubt on this association by reporting cases in which IgM
ANCA were identified, but no alveolar haemorrhage or
other pulmonary manifestations were present [7,11,12].
Some argued that the correlation between alveolar haemor-
rhage and the identification of IgM ANCA was not mean-
ingful, but attributable to the rapidity with which those
who experience alveolar haemorrhage seek medical atten-
tion [12]. That is, investigators are simply less likely to miss
IgM ANCA in a patient with alveolar haemorrhage com-
pared to patients with other disease manifestations.
Our study, which includes considerably more patients
than any previous examination of IgM ANCA, suggests
that there is an increased frequency of alveolar haemor-
rhage among patients with IgM PR3–ANCA, but that the
relationship is not absolute. We also observed patients with
IgM PR3–ANCA who did not have pulmonary manifesta-
tions of AAV, as well as patients with alveolar haemorrhage
who tested negative for IgM PR3–ANCA. It is therefore not
surprising that prior reports with small numbers of
patients found variable clinical correlations for IgM ANCA.
However, we cannot discount the possibility that alveolar
haemorrhage simply reduces the time from symptom onset
to presentation, allowing for a higher probability of observ-
ing the transient IgM ANCA.
Our study has strengths and limitations. Among its
strengths are the number of patients examined and the
comprehensive capturing of clinical data. The most notable
limitation is that we focused only on PR3–ANCA, for sev-
eral reasons. First, we wanted to keep the two cohorts as
similar as possible. Secondly, in contrast to IgM PR3–
ANCA, samples that tested positive for IgM MPO–ANCA
in the RAVE cohort did not test positive on confirmatory
immunofluorescence testing (data not shown).
In conclusion, the pathogenesis of AAV is multi-faceted,
involving a number of host factors and immune pathways.
Insights into the origins and actions of ANCA, including
IgM ANCA, may enhance understanding of the aetiology
and varied clinical presentations of AAV. As shown here,
IgM PR3–ANCA are found transiently in a sizeable number
of patients with active disease, both newly diagnosed and
relapsing. The presence of IgM PR3–ANCA is associated
with a higher degree of disease activity and with a higher
rate of alveolar haemorrhage, which is the most acute and
life-threatening manifestation of AAV. IgM PR3–ANCA
could thus represent a link between infectious triggers and
AAV disease activity.
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